$AIMJun 8, 2026, 8:06 PMAI processedS-1
S-1: Selling holders register 31.3M warrant-backed shares (major potential overhang)
AI Summary
AIM ImmunoTech Inc. filed SEC Form S-1. the 24,328,623 shares outstanding as of May 29, 2026. The company will not receive proceeds from any resale by the selling stockholders, but would receive roughly $14.5 million if all underlying warrants were exercised for cash. Sales and dilution are not immediate — the registration must become effective before resales, and the Class I warrants are not exercisable until the Company obtains the required stockholder approval (they expire five years after the Stockholder Approval Date).
Positives
- If all warrants are exercised for cash, the company would receive approximately $14.5 million
- Company completed a Registered Offering on May 21, 2026 that provided ~$2.4M gross proceeds
Negatives
- Large potential resale overhang: 31.29M warrant-backed shares (~128.6% of pre-offering outstanding shares)
- Full exercise would raise outstanding shares from 24.33M to 55.62M (≈128.6% increase), materially diluting existing holders
- Timing and amount of actual new supply are uncertain — some warrants (Class I) require stockholder approval before exercisable
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: after SEC effectiveness
Dilution status
delayed
Dilution timing
Dilution status: Undetermined
Trigger type
effectiveness